Abstract: The present invention relates to breast cancer and methods for identifying therapeutics and diagnosis. In general, methods for identifying therapeutic agents directed to calcium flow arc disclosed. Also provided arc methods for diagnosis of breast cancer and/or a predisposition to breast cancer and methods of treatment of breast cancer. The methods include identifying therapeutic agents which modulate a CRAC channel and/or a glycoprotein activator of a CRAC channel. Also provided arc diagnostic methods that utilize a CRAC channel and/or a glycoprotein activator of a CRAC channel.

Abstract: The invention provides GmNFR1?, GmNFR1?, GmNFR5?, and GmNFR5? soybean nodulation factor receptor proteins, a receptor complex, and encoding nucleic acids. Also provided are GmNFR1?, GmNFR1?, GmNFR5?, and GmNFR5? promoters, which may be useful for expressing autologous or heterologous sequences in plants, such as soybean. Variant proteins and nucleic acids including RNA splice variants, mis-sense mutants, and non-sense mutants are also described. Also provided are genetically-modified plants and methods of producing genetically-modified plants. Over-expression of soybean nodulation factor receptor proteins by genetically-modified plants may lead to enhanced and/or otherwise facilitated nodulation and/or nitrogen fixation. Genetically-modified plants with down-regulated nodulation factor receptor expression, such as by RNAi or antisense constructs, may exhibit inhibited, diminished, or otherwise reduced nodulation and/or nitrogen fixation.

Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.

Abstract: The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.

Abstract: A Magnetic Resonance Imaging (MRI) phased array head coil (10) comprises an array of coils (1, 2, 3, 4) a decoupling circuit (7) and a decoupling base (14). Counter wound inductors from adjoining coils (1, 2, 3, 4) in the decoupling circuit (7) are interlaced to achieve mutual decoupling between adjoining coils. Each separate coil (1, 2, 3, 4) includes a pair of spaced parallel main conductors (12) located on opposite sides of a cylindrical space (5) enclosed by the coils (1, 2, 3, 4). The decoupling base (14) comprises two meandering conductor bases (8, 9) which are interlaced. Orthogonal main conductors (12) of the coil (1, 2, 3, 4) share a common conductor base (8, 9). The multiple crossings of the paths of the conductor bases (8, 9) reduces mutual coupling effects.

Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.

Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.

Abstract: This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear/non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.

Abstract: A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a ?3 adrenergic receptor agonist.

Abstract: The invention relates to extended release compositions and formulations comprising 6-thioguanine (6-TG), and methods for treating diseases or conditions responsive to 6-TG.

Abstract: This application relates to peptide conjugates comprising peptides that suppress or otherwise inhibit an unwanted or undesirable immune response attached to lipid moieties, and methods for suppressing immune responses, including preventing, inhibiting, treating or decreasing unwanted or undesirable immune responses including autoimmune or allergic immune responses using these peptide conjugates.

Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.

Abstract: The invention provides a polymer composite comprising a thermoplastic host polymer having solid particulate material dispersed therethrough, the host polymer having at least one phase nanodomain, wherein the solid particulate material comprises particles having height, length and width dimensions of which at least one is substantially less than one or both of the other dimensions, and wherein the composite exhibits an increase in modulus of no more than 15% and a higher tensile strength, relative to said host polymer.

Abstract: An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.

Abstract: An apparatus for determining the breakage properties of a particulate material, the apparatus including: a support; a rotor mounted relative to the support and including at least one guide channel through which a particle of the particulate material is guided in use, the guide channel having an inlet and an outlet; a drive associated with the rotor; a feed channel for feeding particles of the particulate material to the inlet of the guide channel; a stator associated with the rotor and including an impact surface that is radially spaced from a circumferential edge of the rotor; and a collector for collecting pieces of the particulate material following impact; wherein the apparatus is provided with a control system for accurate control and adjustment of impact velocity of the particulate material with the impact surface.

Abstract: A method of predicting breakage properties of a particulate material when subjected to impact, the method including: calculating a breakage index for the particulate material using the following equation: Breakage Index=M{I?exp[?fmatxk?E]} where: M represents the maximum breakage of particles for the particulate material; fmat is a material parameter that is a function of the particulate material being broken and particle size; x is the initial particle size of the particulate material prior to impact; E is a measure of the specific energy applied to the particulate material; and k is the number of impacts with specific energy E.

Abstract: The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as acyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation.

Abstract: A method of preparing a porous polymer structure comprising the steps of: forming a liquid composition comprising at least one polymer dissolved in at least one solvent; subjecting the liquid composition to stress, and if necessary also to a reduction in temperature, to cause the liquid composition to form a bi-continuous phase separated composition, the bi-continuous phase separated composition comprising a polymer rich phase and a polymer poor phase; solidifying the at least one polymer in the polymer rich phase; and removing the polymer poor phase from the polymer rich phase to provide the porous polymer structure having a bi-continuous morphology from the polymer rich phase.

Abstract: Disclosed are short chain peptides that are constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials.

Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.